It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Cancer Drug Pexidartinib Filed in Europe: Daiichi Sankyo
April 5, 2019
- Clinigen Gets Japan Rights to Intracerebroventricular Form of Hunter Syndrome Drug Idursulfase Beta
April 5, 2019
- Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
- EquMet Becomes Best Seller for Novartis Japan in FY2018
April 4, 2019
- Japan Pharma Market Skids 1.4% in FY2018: Encise
April 4, 2019
- Gilead’s Biktarvy to Make Japan Debut on April 8
April 4, 2019
- Axcelead Now Independent from Takeda
April 3, 2019
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Telomelysin/Keytruda Combo Shows No Dose-Limiting Toxicities in Interim PIa Data: Oncolys
April 3, 2019
- Xospata Significantly Extends OS in PIII Study in FLT3-Mutated AML: Astellas
April 3, 2019
- Sumitomo Dainippon Files Rethio for Conditioning Treatment Prior to HSCT for Malignant Lymphoma
April 3, 2019
- Nichi-Iko Takes Over Futhan from Torii
April 2, 2019
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
- Chugai Offloading Antiulcer Drug Ulcerlmin to Fuji Chemical
April 2, 2019
- Novel Antibiotic Cefiderocol Accepted for EMA Review: Shionogi
April 2, 2019
- Mundipharma, Maruishi to Copromote Tapenta from June
April 2, 2019
- GSK, Daiichi Sankyo Vaccine Joint Venture Dissolved
April 2, 2019
- Mochida Aims at 108 Billion Yen Sales in FY2021: New 3-Year Biz Plan
April 2, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…